December 2008 Grants
Adinoff, B., NIH, Psychiatrist Research Education and Training in Drug Abuse, $238,331; Boothman, D., NIH/Columbia Univ. Med. Ctr., Center for High Throughput, Minimally Invasive Dosimetry: The IGF-1s CLU Signaling Pathway as a Sensitive Biomarker for Radiation Exposure, $51,237; Burgess, S., NIH, Factors Controlling Metabolic Flux in the Liver by NMR Isotopomer Analysis, $180,000; Castrillon, D., NIH, Regulation of Ovarian Follicle Activation, $188,167; Chen, C., NIH, Asymmetric Synthesis of Biologically Active Marine Natural Products, $153,900.
Chen, D., NIH, Roles of DNA PK in DNA Double-Stranded Break Repair, $236,107; Chiang, C., NIH, Regulation of p53 Transcription by Viral Oncoproteins and Covalent Modifications, $190,000; Chook, Y.M., NIH, Structures and Mechanisms of Nuclear Import and Export, $200,000; Clegg, D., NIH/Univ. of Cincinnati, Insulin and CNS Control of Body Weight and Food Intake, $10,572; Diaz-Arrastia, R., NIH, Genetic Factors in Outcome From Traumatic Brain Injury, $232,204.
Dietschy, J., NIH, UT Gastroenterology/Hepatology Research Training Program, $221,916; Elliott, J., NIH, Mechanisms of SOD1 Toxicity in ALS, $177,188; Freeman, A., NIH/Univ. of Calif., San Francisco, A Community-Level HIV-Prevention Intervention for Young Black Men, $40,557; Forman, J., NIH, Immune Potential of Animal Lacking Class IA Molecules, $200,257; Girard, L., NIH/Vanderbilt Univ. Med. Ctr., Molecular Signature of Lung Cancer, $26,419; Greene, R., NIH, Dopamine Modulation of NMDA Receptor Synaptic Responses, $182,250.
Greene, R., NIH/McLean Hosp., Glutamatergic Dysfunction and Schizophrenia, $53,731; Hansen, E., NIH, Surface Proteins of Moraxella catarrhalis, $225,000; Hardy, R., NIH/UTHSC San Antonio, Role of Unique ADP-Ribosylating Vacuolating Mycoplasma Pneumoniac Toxin in Asthma, $113,305; Huber, K., NIH, Study of Fragile X Mental Retardation Protein in Synaptic Function and Plasticity, $6,627 (supplement); Igarashi, P., NIH, Regulation of Kidney-Specific Gene Expression, $175,565.
Johnson, A., NIH, Role of the Novel Protein Family CAMSAP in Heart, Muscle and Tracheal Development, $33,276; Johnson, J., NIH, Regulation and Function of Ascl1 (Mash1) in Neural Development, $232,659; Kitchens, R., NIH, LPS Efflux From Host Cells to Plasma Lipoproteins, $167,430; Leavey, P., NIH/CureSearch – Natl. Childhood Cancer Fndtn., Children’s Oncology Group, $11,107; Leitch, A.M., NIH/Duke Clinical Research Inst., American College of Surgeons Oncology Group, $9,130.
Leitch, A.M., NIH/Duke Clinical Research Inst., American College of Surgeons Oncology Group, $9,130; Levine, B., NIH/Natl. Space Biomedical Research Inst., The Multisystem Effect of Exercise Training/Nutritional Support During Prolonged Bed-Rest Deconditioning: An Integrative Approach to Countermeasure Development for the Heart, Lungs, Muscles and Bones, $411,518; Lin, R., NIH, Transcriptional Regulation by the Wnt Effector POP-1, $188,167; Link, N., NIH, Neuronal Cell Death in a Genetic Model, $30,372; Margraf, L., NIH/CureSearch – Natl. Childhood Cancer Fndtn., Cancer Therapy Education Program, $4,443.
McClung, C., NIH, Circadian Regulation of Dopaminergic Activity and Restless Legs Syndrome, $98,437; McClung, C., NIH, Role of the Circadian Clock in the Development and Treatment of Mood Disorders, $200,000; McKnight, S., NIH,/Northwestern Univ., Chemical and Genetic Manipulation of Circadian Systems, $165,607; Medin, P., NIH, Spinal-Cord Tolerance to Radiosurgical Dose Delivery, $107,309; Mendelson, C., NIH, Initiation of Human Labor: Prevention of Prematurity, $838,693.
Minei, J., NIH/Mass. General Hosp., Inflammation and the Host Responses to Injury, $160,835; Mumby, M., NIH, Cell-Cycle Regulation by Protein Phosphatase 2 A, $200,000; Olson, E., NIH, Control of Cardiac Gene Expression Through Regulated Transcriptional Coactivators, $415,029; Orth, K., NIH, Biochemical Characterization of Yersinia Effector YopK, $180,000; Phelps, K., NIH, Robotics and Data Storage for High Content Screening, $136,962.
Richards, B., NIH/UTHSC Houston, Genetic Studies of Clubfoot, $21,878; Rogers, Z., NIH/St. Jude Children’s Research Hosp., Stroke With Transfusions Changing to Hydroxyurea, $47,624; Rosen, M., NIH, Structural Study of GTPase Regulators and Effectors, $172,308; Rutherford, C., NIH/ UTHSC Houston, Region IV Comprehensive Hemophilia Program, $31,053; Scheuermann, R., NIH/UTHSC Houston, $15,924.
Tamminga, C., NIH.Mt. Sinai School of Med., Neural Substrates of Appetitive Behavior in Mood and Motivation, $47,100; Thorpe, P., NIH/Duke Univ. Med. Ctr., To Develop New Immunization Strategies to Promote Survival and Expansion of the B-Cell Compartment That Produces Antibodies Against Broadly Reactive Neutralizing Determinants of HIV-1 Env, $79,007; Varley, A., NIH, Interactions of Endotoxin With Plasma and Cells, $263,883; Wang, J., NIH/Univ. of Calif., Davis, AMBER Force Field Consortium, $44,586.
White, M., NIH, Components of Ras-Mediated Growth Control, $149,830; White, M., NIH, Components of Ras-Mediated Growth Control, $35,830 (supplement); White, M., NIH, Components of Ras-Mediated Growth Control, $33,980 (supplement).
Coppari, R., AHA, The Physiological Relevance of SIRT 1 in Brain of Body Energy Metabolism, $70,000; Li, S., Paralyzed Veterans of America, Promote Spinal Cord Axon Regeneration With Novel Peptides Against CSPGs, $69,440; Scherer, P., Eli Lilly, Denis McGarry Symposium, $10,000; Weitzul, S., Amer. Soc. for Dermatologic Surgery, Prolonged Intradermal Support for Prevention of Postoperative Scar Spread, $5,500.
Pharmaceutical studies, dollar amounts not available
Auchus, R., A Randomized, Double-Blind Study to Assess the Safety and Efficacy of Different Dose Levels of Study Drug over a Six-Month Treatment Period in Patients With De Novo, Persistent or Recurrent Cushing’s Disease; Bowers, D., Randomized, Double-Blind, Placebo-Controlled Study of Efficacy and Safety of Study Drug in Preadolescent and Adolescent Children With Attention Impairment Following Cancer Treatment; Carr, B., A Multicenter, Randomized, Double-Blind, Parallel-Group Study to Evaluate the Efficacy and Safety of Two Doses of Study Drug versus Placebo in Women With Overactive Bladder; Jain, M., Differences in Knowledge and Perceptions Affecting Treatment Seeking and Adherence Behaviors Among HCV Mono-infected and HIV/HCV Co-infected Patients.
Kenkel, J., A Multicenter, Randomized, Controlled Study With Independent, Masked Assessment to Evaluate the Safety and Efficacy of the Study Device for Noninvasive Abdominal Fat Reduction for the Purpose of Body Countouring; Lee, W., A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Eltrombopag to Reduce the Need for Platelet Transfusion in Thrombocytopenic Subjects With Chronic Liver Disease Undergoing Elective Invasive Procedures; Miller, D., A Non-Interventional Prospective Study of the Correlation of the Precision Therapeutics Chemoresponse Assay With Progression-Free Survival in Patients With Recurrent Epithelial Ovarian, Peritoneal, or Fallopian Tube Cancer.
Okada, P., The Increased Flow Utilizing Subcutaneously-Enabled Pediatric Rehydration II Study: Subcutaneous Rehydration With Recombinant Human Hyaluronidase (Hylenex) Compared to Intravenous Rehydration in Infants and Young Children With Mild to Moderate Dehydration; Pandya, A., A Phase 4, Open-Label Study to Assess the Long-Term Safety of Study Drug in the Treatment of Seborrheic Dermatitis; Sinclair, G., Effect of Study Drug on HIV RNA Levels in Cerebrospinal Fluid; Verity, S., Evaluation of Clinical and Biological Data Collected From Dry-Eyed Individuals.
Weiner, M., A 52-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With Mild Alzheimer’s Disease to Investigate the Safety and Tolerability of Repeated Subcutaneous Injections of Study Drug.